相关实验视频
Updated: Feb 4, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
17.0K
焦点肝脏PSMA吸收对应于肥胖症节省区域:一个诊断陷
Hasan Önner1, Merve Nida Calderon Tobar, Kevser Oksuzoglu
1Department of Nuclear Medicine, Faculty of Medicine, Selcuk University, Konya, Turkey.
Clinical nuclear medicine
|February 2, 2026
概括
肝脏增加的-68 (68Ga) PSMA吸收可以模仿前列腺癌转移. 在68Ga-PSMA PET/CT扫描中避免误诊,识别节省成像时间的肥胖症至关重要.
科学领域:
- 核医学就是核医学.
- 放射性药物 放射性药物 放射性药物
- 在瘤学瘤学.
背景情况:
- -68 (68Ga) -PSMA PET/CT 是前列腺癌的关键成像方式.
- 肝脏中PSMA吸收的解释可能具有挑战性.
- 肝硬化可以影响PSMA吸收模式.
研究的目的:
- 描述一个肝脏部分68Ga-PSMA摄入量增加的病例,而肝脏部分没有发生牛脂病.
- 要突出这一发现被误解为转移的可能性.
- 强调对成像发现的相关性的重要性.
主要方法:
- 案例报告的呈现方式.
- 对68Ga-PSMA PET/CT成像的审查.
- 与CT和MRI检测结果的相关性,以评估肝肥胖症.
主要成果:
- 鉴定了肝脏部分3的68Ga-PSMA吸收的焦点增加.
- 这一区域免于扩散性肝肥胖症.
- 吸收模式模仿了PET/CT的焦点肝转移.
结论:
- 增加68Ga-PSMA的摄取量在脂肪节省的肝脏部分可以模仿转移.
- 准确的解释需要与CT/MRI的相关性来识别脂肪.
- 识别良性变异对于正确的68Ga-PSMA PET/CT解释至关重要.
更多相关视频
相关概念视频
Spare Receptors
4.6K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.6K
Intracellular Signaling Affects Focal Adhesions
3.6K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
280
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System
5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Antihypertensive Drugs: Potassium-Sparing Diuretics
2.3K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
244
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244

